Prolonged hyperglycemia in DME patients causes hypoxia and inflammation, resulting in an upregulation of growth factors and cytokines, e.g. vascular endothelial growth factor (VEGF) [4] which is essential for causing vascular leakage and acts as an proinflammatory cytokine in the pathogenesis of DME [2]; thus, the intravitreal anti-VEGF injection is now a standard treatment for DME [5, 6]. Here, VEGFA is linked to Hyperglycemia.